Complete remission after fludarabine for chronic lymphocytic leukemia.
Johnson
S A
SA
Richardson
D
D
Hopkins
J
J
Howe
D
D
Phillips
M J
MJ
D015703:Antigens, CD / Q000032:analysis; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015139:Blotting, Southern; D001853:Bone Marrow / Q000473:pathology; D004273:DNA, Neoplasm / Q000235:genetics / Q000302:isolation & purification; D004334:Drug Administration Schedule; D006684:HLA-DR Antigens / Q000032:analysis; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016133:Polymerase Chain Reaction / Q000379:methods; D013997:Time Factors; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
D015703:Antigens, CD; D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D006684:HLA-DR Antigens; D007143:Immunoglobulin Heavy Chains; D014740:Vidarabine; C024352:fludarabine